TerminatedNCT06628622
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Addiction Who Are Taking Buprenorphine
Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Los Alamitos and 4 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 27, 2025
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 12
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06628622
- Official title
Show the full official title
A Phase Ib, Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial to Evaluate the Effects on Impulsivity, Pharmacokinetics, Safety, and Tolerability of Oral BI 1356225 in Patients With Opioid Use Disorder Taking Background Buprenorphine Treatment
Recruitment & locations
TerminatedLos Alamitos · Los Angeles · Decatur
2 more locations
- Marlton
- Richmond
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Does this study involve medication?
Yes. The study involves medication, including BI 1356225 and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
